Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
A Phase I, Multi-center, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ASKC189 in Chinese Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors Carrying RAS Gene Mutations.
This is a phase I study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ASKC189 in in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Jiangsu Aosaikang Study Director
- Numero di telefono: +86 025 52169999
- Email: ctr-contact@ask-pharm.com
Luoghi di studio
-
-
-
Beijing, Cina
- Peking University Cancer Hospital
-
Investigatore principale:
- Lin Shen, MD
-
Shanghai, Cina
- Shanghai East Hospital
-
Investigatore principale:
- Caicun Zhou, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Aged ≥18 years old at the time of informed consent
- Able to provide informed consent voluntarily before any study-related activities and according to local guidelines
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Have an estimated life expectancy ≥ 12 weeks
- Have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic with progression after treatment with available standard therapies.
- Documentation of KRAS/NRAS/HRAS mutation determined by validated local testing of tumor tissue or circulating free DNA (cfDNA) in a certified laboratory
- Have consented to provide archival tumor tissue collected within 3 years or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated.
- Have adequate organ functions
- Have discontinued all previous treatments for cancer with resolution of any adverse events (AEs) to ≤ Grade 1
Exclusion Criteria:
- Are currently enrolled in a clinical study involving an investigational product or any other type of medical research
- Have tumors previously tested positive for Class I BRAF mutations i.e. V600X
- Prior treatment with a pan-RAS(ON) inhibitor
- Gastrointestinal conditions that may interfere with drug absorption
- Have a serious concomitant systemic disorder
- Have a serious pre-existing medical condition(s)
- Prior or second concurrent primary malignancies
- Moderate or severe cardiovascular disease
- Have symptomatic central nervous system (CNS) malignancy or metastasis
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: ASKC189 oral capsule
|
ASKC189 for every cycle of 21 days until disease progression or other criteria for treatment discontinuation will be met. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The incidence and case number of DLT (Dose Limiting Toxicity) during observation period
Lasso di tempo: Up to 21 days following first dose
|
DLT is short for Dose Limiting Toxicity, dose-limiting describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment. |
Up to 21 days following first dose
|
|
Number of participants with adverse events and serious adverse events as assessed by CTCAE v6.0
Lasso di tempo: Up to 30 days following last dose
|
AE refers to any untoward medical occurrence or deterioration of existing medical event after the investigational treatment, whether or not considered related to the study treatment. |
Up to 30 days following last dose
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Characterization of the PK profile of ASKC189
Lasso di tempo: At time points pre-dose, 1, 2, 4, 6, 8, 24 hours post dose
|
AUC(inf) after single dose and AUC (0-τ) after single and multiple doses Maximum blood concentration (Cmax) |
At time points pre-dose, 1, 2, 4, 6, 8, 24 hours post dose
|
|
Characterization of the PK profile of ASKC189: blood concentration characteristics
Lasso di tempo: At time points pre-dose, 1, 2, 4, 6, 8, 24 hours post dose
|
Time to maximum blood concentration (Tmax) |
At time points pre-dose, 1, 2, 4, 6, 8, 24 hours post dose
|
|
Characterization of the PK profile of ASKC189: steady state characterization
Lasso di tempo: At time points pre-dose, 1, 2, 4, 6, 8, 24 hours post dose
|
Accumulation ratio (AR) at steady-state |
At time points pre-dose, 1, 2, 4, 6, 8, 24 hours post dose
|
|
Characterization of the PK profile of ASKC189: drug level characterization in blood
Lasso di tempo: At time points pre-dose, 1, 2, 4, 6, 8, 24 hours post dose
|
Apparent clearance (CL/F) after single and multiple doses |
At time points pre-dose, 1, 2, 4, 6, 8, 24 hours post dose
|
|
Characterization of the PK profile of ASKC189
Lasso di tempo: At time points pre-dose, 1, 2, 4, 6, 8, 24 hours post dose
|
ASKC189 apparent terminal half-life (t1/2) |
At time points pre-dose, 1, 2, 4, 6, 8, 24 hours post dose
|
|
Objective response rate (ORR)
Lasso di tempo: Up to approximately 3 years
|
ORR is defined as the proportion of subjects with confirmed CR or confirmed PR (based on RECIST Version 1.1). |
Up to approximately 3 years
|
|
Disease control rate (DCR)
Lasso di tempo: Up to approximately 3 years
|
DCR is defined as the proportion of subjects with CR, PR, or SD (based on RECIST Version 1.1). |
Up to approximately 3 years
|
|
Duration of Response (DoR)
Lasso di tempo: Up to approximately 3 years
|
DoR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST Version 1.1) or death due to any cause, whichever occurs first. |
Up to approximately 3 years
|
|
Progression-free survival (PFS)
Lasso di tempo: Up to approximately 3 years
|
PFS is defined as the time from the start of treatment until the first documentation of disease progression (based on RECIST Version 1.1) or death due to any cause, whichever occurs first. |
Up to approximately 3 years
|
|
Overall survival (OS)
Lasso di tempo: Up to approximately 3 years
|
OS defined as the time from the first dose to death from any cause. |
Up to approximately 3 years
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The identification of potential predictive biomarkers associated with response or resistance to ASKC189
Lasso di tempo: Up to approximately 3 years
|
Correlation of clinical outcomes with biomarkers to specific RAS mutation subtypes, and co-mutations in tumor tissue at baseline and progressive disease. |
Up to approximately 3 years
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- ASKC189-102
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .